Evogene Ltd (NASDAQ:EVGN) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 27,400 shares, a growth of 14.6% from the July 31st total of 23,900 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 10,900 shares, the short-interest ratio is currently 2.5 days.
EVGN traded down $0.01 during midday trading on Friday, hitting $1.62. The company had a trading volume of 7,000 shares, compared to its average volume of 9,965. The company has a current ratio of 10.14, a quick ratio of 10.14 and a debt-to-equity ratio of 0.06. Evogene has a twelve month low of $1.34 and a twelve month high of $3.32. The firm’s 50-day simple moving average is $1.57 and its 200-day simple moving average is $1.77.
Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.35). The company had revenue of $0.19 million during the quarter. Evogene had a negative net margin of 1,193.65% and a negative return on equity of 37.62%.
A number of institutional investors and hedge funds have recently bought and sold shares of EVGN. Meitav Dash Investments Ltd. increased its position in Evogene by 44.7% in the 1st quarter. Meitav Dash Investments Ltd. now owns 28,521 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 8,804 shares in the last quarter. ARK Investment Management LLC increased its position in Evogene by 13.7% in the 1st quarter. ARK Investment Management LLC now owns 286,748 shares of the biotechnology company’s stock valued at $525,000 after acquiring an additional 34,626 shares in the last quarter. Delek Group Ltd. increased its position in Evogene by 4.2% in the 1st quarter. Delek Group Ltd. now owns 217,824 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 8,717 shares in the last quarter. Eidelman Virant Capital acquired a new stake in Evogene in the 2nd quarter valued at about $102,000. Finally, Senvest Management LLC increased its position in Evogene by 201.1% in the 2nd quarter. Senvest Management LLC now owns 414,682 shares of the biotechnology company’s stock valued at $668,000 after acquiring an additional 276,943 shares in the last quarter. Hedge funds and other institutional investors own 29.23% of the company’s stock.
Separately, ValuEngine raised shares of Evogene from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.
Recommended Story: Stop Order
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.